Le Lézard
Classified in: Health, Business
Subjects: NPT, LEG, POL

Nation's Kidney Community Applauds Introduction of Bipartisan Legislation to Protect Insurance Access for Individuals Living with Kidney Failure


WASHINGTON, Aug. 1, 2022 /PRNewswire/ -- Kidney Care Partners (KCP) ? the nation's largest non-profit, non-partisan coalition of more than 30 organizations representing patients, professional care providers, and a wide range of kidney care stakeholders ? applauded the introduction of the bipartisan bill in the U.S. House of Representatives, H.R. 8594, to amend title XVIII of the Social Security Act to clarify and preserve the breadth of the protections under the Medicare Secondary Payer Act. Sponsored by Representatives Yvette Clarke (D-NY), Jodey Arrington (R-TX), Buddy Carter (R- GA) and Danny Davis (D-IL), the legislation, if passed, would restore protections intended by Congress in the original enactment of the language at issue in the Medicare Secondary Payor Act and ensure individuals living with end stage renal disease (ESRD) ? or kidney failure --  cannot be discriminated against based on their need for dialysis.

"KCP thanks Representatives Clarke, Arrington, Carter and Davis for their leadership on this bill and for acting quickly to address the troubling efforts of private insurers to force individuals requiring dialysis care out of their preferred plan," said Michele Kimball, executive director of KCP. "This legislation will prevent harm to these vulnerable individuals by eliminating any distinction among patients by insurers based on their need for dialysis care, which we believe was always the true intent of the Medicare Secondary Payer Act. It will also help to reinforce the Medicare Part A Trust Fund, which is increasingly underfunded."

"As someone who has personally and painfully experienced the limitations of Medicare when needing a new wheelchair, I applaud this effort to protect a patient's right to choose the best coverage option for themselves," said Dialysis Patient Citizens (DPC) Board of Directors President Andrew Conkling. "Preserving an individual's right to continue their private insurance plan allows for continuity of care and creates an incentive for insurers to cover detection and treatment of chronic kidney disease. Detection and care for early kidney disease can help delay the need for dialysis- ultimately creating cost savings and improving outcomes. Passage of H.R. 8594 would be a win not just for those already living on dialysis but for any American living with or at risk of kidney disease."

Earlier this year, KCP expressed concern that health plans discriminated against those with end-stage renal disease (ESRD) by limiting coverage of life-sustaining treatment, ultimately driving patients to drop their private group coverage, many of which included additional financial protections for both them and their families, in favor of Medicare. This issue was recently considered by the Supreme Court in the Marietta Memorial Hospital Employee Benefit Health Plan v. DaVita case.

"Fundamentally, this is a coverage and cost issue ? one that directly impacts patients' ability to afford needed kidney care while further reducing equity among patients in accessing it. Passage of H.R. 8594 will once and for all prevent insurers from pushing dialysis patients prematurely from private insurance into the Medicare program. Its' passage would be a win for patients and the American taxpayer, and KCP urges Congress to act swiftly on this important measure," Kimball concluded.

SOURCE Kidney Care Partners


These press releases may also interest you

at 06:05
Dr. Majid Al Fayyadh, CEO of King Faisal Specialist Hospital and Research Centre (KFSH&RC) joined the Gulf Creatives Conference (GCC) at Harvard 2024. The event, GCC at Harvard, is organized by The Diwan, an organization run by graduate students at...

at 06:00
Replicate Bioscience, a clinical-stage company pioneering novel self-replicating RNA (srRNA) technology for use across a range of infectious disease, oncology,...

at 03:14
Caliway Biopharmaceuticals (Caliway) is pleased to announce its participation to share the latest clinical advancements at the upcoming 2024 BIO International Convention on Wednesday, June 5th, at 11:45 a.m. PDT. The presentation will take place in...

10 mai 2024
On May 10, 2024, the impactful international academic journal, Science Immunology, a sub-journal of Science, published a research paper titled "Single-cell analysis of anti-BCMA CAR T cell therapy in patients with central nervous system...

10 mai 2024
Fitness International, LLC opened a new Club Studio location in Kingwood, Texas. The new 40,000 square foot club features five innovative boutique fitness studios that were carefully curated to create a unique experience, along with recovery services...

10 mai 2024
Mirum Pharmaceuticals, Inc. today announced that on May 10, 2024, the Compensation Committee of Mirum's Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 38,600 shares of common stock and 19,300...



News published on and distributed by: